Şahin Avcı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Şahin Avcı has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Zehra Oya Uyguner
Department of Medical Genetics, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
9 shared publications - Umut Altunoglu
Department of Medical Genetics, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
8 shared publications - Güven Toksoy
Department of Medical Genetics, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
6 shared publications - Hülya Kayserili
Research Center for Translational Medicine (KUTTAM), Koç University School of Medicine (KUSoM), Istanbul, Turkey
6 shared publications - Seher Başaran
Department of Medical Genetics, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
5 shared publications - Birsen Karaman
Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
4 shared publications
Latest Publications
- 4 August 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (5) , 549-557
Hereditary Polyneuropathy Experience of a Tertiary Single‐Center in Türkiye: Beyond the Tip of the Iceberg
Hereditary polyneuropathies (HPPs), including Charcot–Marie–Tooth disease (CMT), represent a genetically and clinically heterogeneous group of disorders. Overlapping phenotypes, genetics, and clinical heterogeneity, and more complex phenotypes mimicking CMT can complicate the diagnosis. This study evaluated the effectiveness of an algorithm‐guided, broad genetic testing strategy in a tertiary neuromuscular center in Türkiye, where recessive disorders are relatively common. Sixty‐seven patients from 63 families referred for suspected HPP (2018–2025) were clinically stratified by phenotype and electrophysiology, and a diagnostic workflow integrating PMP22 MLPA with clinical or whole‐exome sequencing was applied. The overall molecular diagnostic yield was 73% (46/63). PMP22 ‐related neuropathies accounted for 43.5% of all diagnosed cases, with a group‐specific yield of 60%. Among the non‐ PMP22 CMT group, the predominant inheritance pattern was autosomal recessive (70%). Nine novel variants were identified. Two dual molecular diagnoses ( PMP22 / MCCC1 ; MPZ / CRYBB2 ) were established. Importantly, six patients initially labeled as “CMT‐like” harbored non‐CMT disorders, including CYP27A1 ‐, BTD ‐, HEXB ‐, ZFYVE26 ‐, C19ORF12 ‐, and COA7 ‐related diseases—several of which are treatable or actionable. In a population with high genetic heterogeneity and elevated consanguinity, reliance on narrow CMT‐focused panels risks misdiagnosis and may miss therapeutic opportunities. An algorithm‐driven approach integrating PMP22 CNV analysis with exome sequencing substantially improves diagnostic yield, reveals blended or digenic mechanisms, and helps distinguish non‐CMT phenocopies. These findings underscore the importance of comprehensive genomic testing and careful phenotype–genotype correlation in the evaluation of hereditary polyneuropathies.
- 4 August 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (5) , 549-557
Hereditary Polyneuropathy Experience of a Tertiary Single‐Center in Türkiye: Beyond the Tip of the Iceberg
Hereditary polyneuropathies (HPPs), including Charcot–Marie–Tooth disease (CMT), represent a genetically and clinically heterogeneous group of disorders. Overlapping phenotypes, genetics, and clinical heterogeneity, and more complex phenotypes mimicking CMT can complicate the diagnosis. This study evaluated the effectiveness of an algorithm‐guided, broad genetic testing strategy in a tertiary neuromuscular center in Türkiye, where recessive disorders are relatively common. Sixty‐seven patients from 63 families referred for suspected HPP (2018–2025) were clinically stratified by phenotype and electrophysiology, and a diagnostic workflow integrating PMP22 MLPA with clinical or whole‐exome sequencing was applied. The overall molecular diagnostic yield was 73% (46/63). PMP22 ‐related neuropathies accounted for 43.5% of all diagnosed cases, with a group‐specific yield of 60%. Among the non‐ PMP22 CMT group, the predominant inheritance pattern was autosomal recessive (70%). Nine novel variants were identified. Two dual molecular diagnoses ( PMP22 / MCCC1 ; MPZ / CRYBB2 ) were established. Importantly, six patients initially labeled as “CMT‐like” harbored non‐CMT disorders, including CYP27A1 ‐, BTD ‐, HEXB ‐, ZFYVE26 ‐, C19ORF12 ‐, and COA7 ‐related diseases—several of which are treatable or actionable. In a population with high genetic heterogeneity and elevated consanguinity, reliance on narrow CMT‐focused panels risks misdiagnosis and may miss therapeutic opportunities. An algorithm‐driven approach integrating PMP22 CNV analysis with exome sequencing substantially improves diagnostic yield, reveals blended or digenic mechanisms, and helps distinguish non‐CMT phenocopies. These findings underscore the importance of comprehensive genomic testing and careful phenotype–genotype correlation in the evaluation of hereditary polyneuropathies.
- 19 July 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (4) , 471-479
Clinical and Molecular Characterization of a RASopathy Cohort From Türkiye and an AMMECR1 ‐Related Noonan Syndrome‐Mimicking Phenotype
RASopathies comprise a group of congenital malformation syndromes with predominant neuro‐cardio‐facial‐cutaneous involvement resulting from pathogenic variants in RAS/mitogen‐activated protein kinase (MAPK) signaling pathway genes. In this study 33 patients are presented with their clinical and molecular findings as an RASopathy cohort including a family with an AMMECR1 ‐related disorder. The diagnostic distribution of the cohort included Noonan syndrome ( n = 18), neurofibromatosis type 1 ( n = 8), and single cases of cardiofaciocutaneous syndrome, Costello syndrome, neurofibromatosis‐Noonan syndrome, NF1 microdeletion syndrome, Noonan syndrome‐like disorder with loose anagen hair, Noonan syndrome with multiple lentigines and AMMECR1 ‐related midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis (MIM# 300990). The most prevalent clinical manifestations were dermatological findings (90.9%), skeletal features (84.4%), cardiovascular involvement (75.8%), and typical craniofacial dysmorphism suggestive of RASopathy (72.7%). Variants were most frequently identified in PTPN11 and NF1 , followed by single cases involving the BRAF , HRAS , LZTR1 , RAF1 , RIT1 , SHOC2 , and SOS1 . Notably, one patient harbored a variant in AMMECR1 , which is not involved in the RAS/MAPK pathway. Overall, this study delineates the clinical and molecular landscape of a cohort from Türkiye and underscores that the AMMECR1 ‐related phenotype represents a distinct entity that closely mimics Noonan syndrome.
- 19 July 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (4) , 471-479
Clinical and Molecular Characterization of a RASopathy Cohort From Türkiye and an AMMECR1 ‐Related Noonan Syndrome‐Mimicking Phenotype
RASopathies comprise a group of congenital malformation syndromes with predominant neuro‐cardio‐facial‐cutaneous involvement resulting from pathogenic variants in RAS/mitogen‐activated protein kinase (MAPK) signaling pathway genes. In this study 33 patients are presented with their clinical and molecular findings as an RASopathy cohort including a family with an AMMECR1 ‐related disorder. The diagnostic distribution of the cohort included Noonan syndrome ( n = 18), neurofibromatosis type 1 ( n = 8), and single cases of cardiofaciocutaneous syndrome, Costello syndrome, neurofibromatosis‐Noonan syndrome, NF1 microdeletion syndrome, Noonan syndrome‐like disorder with loose anagen hair, Noonan syndrome with multiple lentigines and AMMECR1 ‐related midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis (MIM# 300990). The most prevalent clinical manifestations were dermatological findings (90.9%), skeletal features (84.4%), cardiovascular involvement (75.8%), and typical craniofacial dysmorphism suggestive of RASopathy (72.7%). Variants were most frequently identified in PTPN11 and NF1 , followed by single cases involving the BRAF , HRAS , LZTR1 , RAF1 , RIT1 , SHOC2 , and SOS1 . Notably, one patient harbored a variant in AMMECR1 , which is not involved in the RAS/MAPK pathway. Overall, this study delineates the clinical and molecular landscape of a cohort from Türkiye and underscores that the AMMECR1 ‐related phenotype represents a distinct entity that closely mimics Noonan syndrome.
- 18 February 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (3) , 438-447
Prenatal and Postmortem Characterization of FGFR2 ‐Related Fetal Craniosynostosis: Emphasizing Rare and Atypical Anomalies
Objective: Craniosynostosis (CS) is the second most common craniofacial birth defect after orofacial clefts. Genetic counseling is essential for reproductive planning in affected families. Methods: Nine fetal CS cases—six Apert syndrome (AS) and three Pfeiffer syndrome (PS)—with established genetic causes were retrospectively analyzed for clinical, radiological, and molecular features. Results: Mean gestational age at first examination was 26.2 weeks. Four AS and two PS cases were diagnosed during the prenatal stage by ultrasonography (USG), whereas two AS and one PS cases were identified during postmortem. Common prenatal findings included polyhydramnios, high flat forehead, and syndactyly. Two of the three cases diagnosed at the postmortem stage had multiple congenital anomalies (MCA), while in the third, CS was suspected due to frontal bossing and proptosis despite the absence of classic signs. All cases carried pathogenic FGFR2 variants. Conclusions: Proptosis, frontal bossing, and trigonocephaly are key prenatal indicators of CS, but their absence—especially with systemic anomalies—can challenge diagnosis. In cases with MCA, CS should be suspected even if classic signs are absent, particularly when syndactyly accompanies other complex abnormalities. Postmortem evaluation and molecular genetic testing are essential for definitive diagnosis, especially when clinical features are ambiguous.
- 18 February 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (3) , 438-447
Prenatal and Postmortem Characterization of FGFR2 ‐Related Fetal Craniosynostosis: Emphasizing Rare and Atypical Anomalies
Objective: Craniosynostosis (CS) is the second most common craniofacial birth defect after orofacial clefts. Genetic counseling is essential for reproductive planning in affected families. Methods: Nine fetal CS cases—six Apert syndrome (AS) and three Pfeiffer syndrome (PS)—with established genetic causes were retrospectively analyzed for clinical, radiological, and molecular features. Results: Mean gestational age at first examination was 26.2 weeks. Four AS and two PS cases were diagnosed during the prenatal stage by ultrasonography (USG), whereas two AS and one PS cases were identified during postmortem. Common prenatal findings included polyhydramnios, high flat forehead, and syndactyly. Two of the three cases diagnosed at the postmortem stage had multiple congenital anomalies (MCA), while in the third, CS was suspected due to frontal bossing and proptosis despite the absence of classic signs. All cases carried pathogenic FGFR2 variants. Conclusions: Proptosis, frontal bossing, and trigonocephaly are key prenatal indicators of CS, but their absence—especially with systemic anomalies—can challenge diagnosis. In cases with MCA, CS should be suspected even if classic signs are absent, particularly when syndactyly accompanies other complex abnormalities. Postmortem evaluation and molecular genetic testing are essential for definitive diagnosis, especially when clinical features are ambiguous.
- 26 December 2025
- Published by Wiley in Clinical Genetics
- Vol. 109 (5) , 889-903
Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants
Congenital myasthenic syndrome (CMS) refers to a rare heterogeneous group of hereditary disorders characterized by fatigue and muscle weakness due to impairment in neuromuscular transmission. A total of 40 genes have been identified in the pathogenesis of CMSs. The study assessed 22 patients (14 females and 8 males) with CMS of childhood onset with their phenotypes and genotypes. Genetic analysis revealed variations in the following eight genes: CHRNE , DOK7 , GFPT1 , COLQ , SLC25A1 , CHAT , MUSK , and MYO9A. Eight novel variations were detected involving SLC25A1 , MUSK , DOK7 , GFPT1 , and CHRNE . The median age was 14 years (range: 0.5–67 years). The median age of onset of symptoms was 8 months (range: 0–16 years). The longest time after the onset of symptoms was 62 years. The most common initial symptoms were weakness of extremities ( n = 9) and ptosis ( n = 8). Respiratory symptoms were present in 11 patients (50%), which showed progression, multiphasic disease course, and amelioration in 45.4%, 18.1%, and 36.3% of patients, respectively. Motor symptoms showed a progressive worsening in 68.1%, stationary course in 13.6%, multiphasic disease course in 13.6%, and amelioration in 4.5% of patients. Thanks to next‐generation sequencing, diagnoses of CMS have been increasing over the recent years; so has the number of novel variants.
- 26 December 2025
- Published by Wiley in Clinical Genetics
- Vol. 109 (5) , 889-903
Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants
Congenital myasthenic syndrome (CMS) refers to a rare heterogeneous group of hereditary disorders characterized by fatigue and muscle weakness due to impairment in neuromuscular transmission. A total of 40 genes have been identified in the pathogenesis of CMSs. The study assessed 22 patients (14 females and 8 males) with CMS of childhood onset with their phenotypes and genotypes. Genetic analysis revealed variations in the following eight genes: CHRNE , DOK7 , GFPT1 , COLQ , SLC25A1 , CHAT , MUSK , and MYO9A. Eight novel variations were detected involving SLC25A1 , MUSK , DOK7 , GFPT1 , and CHRNE . The median age was 14 years (range: 0.5–67 years). The median age of onset of symptoms was 8 months (range: 0–16 years). The longest time after the onset of symptoms was 62 years. The most common initial symptoms were weakness of extremities ( n = 9) and ptosis ( n = 8). Respiratory symptoms were present in 11 patients (50%), which showed progression, multiphasic disease course, and amelioration in 45.4%, 18.1%, and 36.3% of patients, respectively. Motor symptoms showed a progressive worsening in 68.1%, stationary course in 13.6%, multiphasic disease course in 13.6%, and amelioration in 4.5% of patients. Thanks to next‐generation sequencing, diagnoses of CMS have been increasing over the recent years; so has the number of novel variants.
- Open Access
- 2 April 2025
- Published by Wiley in Clinical Genetics
- Vol. 108 (3) , 334-346
Aarskog Syndrome: Deep Phenotyping and Genomic Landscape of a New Cohort Including Adult Patients
Aarskog‐Scott syndrome (AAS, MIM#305400) is an X‐linked disorder characterized by recognizable facial features, short stature, and genitourinary and skeletal malformations. AAS is attributed to pathogenic variants in FGD1, and ~60 patients with a genetic diagnosis have been reported to date. We hereby present a molecularly confirmed cohort of 14 male AAS patients from 13 families. Among 14 patients, 12 were referred during childhood, while two were referred at adulthood due to infertility. Six out of 11 patients with available records had antenatal manifestations, comprising shortened tubular bones, growth restriction, polyhydramnios, pes equinovarus, increased nuchal translucency, fetal hypokinesia, echogenic intracardiac focus, and ambiguous genitalia. In addition to well‐described AAS findings, distinctive features observed in multiple patients included variable skin findings (n = 5), renal malformations (n = 2), muscular build (n = 2), and infertility (n = 2). Cardiac (n = 4) and ocular manifestations (n = 6) were identified at significantly higher rates than previously reported. This cohort also presents new patients with osteochondritis dissecans and oligo/azoospermia, providing further evidence to acknowledge these once‐reported findings as part of the disease spectrum. Eleven different FGD1 variants, including seven novel ones, were identified through targeted FGD1 sequencing. Two variants were found to be recurrent, detected in two independent families. Our study provides additional insights into the clinical and genotypic landscape of AAS through the largest molecularly confirmed cohort, including two adult patients.
- 2 April 2025
- Published by Wiley in Clinical Genetics
- Vol. 108 (3) , 334-346
Open AccessAarskog Syndrome: Deep Phenotyping and Genomic Landscape of a New Cohort Including Adult Patients
Aarskog‐Scott syndrome (AAS, MIM#305400) is an X‐linked disorder characterized by recognizable facial features, short stature, and genitourinary and skeletal malformations. AAS is attributed to pathogenic variants in FGD1, and ~60 patients with a genetic diagnosis have been reported to date. We hereby present a molecularly confirmed cohort of 14 male AAS patients from 13 families. Among 14 patients, 12 were referred during childhood, while two were referred at adulthood due to infertility. Six out of 11 patients with available records had antenatal manifestations, comprising shortened tubular bones, growth restriction, polyhydramnios, pes equinovarus, increased nuchal translucency, fetal hypokinesia, echogenic intracardiac focus, and ambiguous genitalia. In addition to well‐described AAS findings, distinctive features observed in multiple patients included variable skin findings (n = 5), renal malformations (n = 2), muscular build (n = 2), and infertility (n = 2). Cardiac (n = 4) and ocular manifestations (n = 6) were identified at significantly higher rates than previously reported. This cohort also presents new patients with osteochondritis dissecans and oligo/azoospermia, providing further evidence to acknowledge these once‐reported findings as part of the disease spectrum. Eleven different FGD1 variants, including seven novel ones, were identified through targeted FGD1 sequencing. Two variants were found to be recurrent, detected in two independent families. Our study provides additional insights into the clinical and genotypic landscape of AAS through the largest molecularly confirmed cohort, including two adult patients.
- 7 May 2024
- Published by Wiley in Epileptic Disorders
- Vol. 26 (3) , 392-394
A genetic cause for intractable seizures: Atypical Gaucher disease with a novel pathological variant
- 7 May 2024
- Published by Wiley in Epileptic Disorders
- Vol. 26 (3) , 392-394
A genetic cause for intractable seizures: Atypical Gaucher disease with a novel pathological variant
- Open Access
- 21 November 2023
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 15 (4) , 338-347
PROKR2 Mutations in Patients with Short Stature Who Have Isolated Growth Hormone Deficiency and Multiple Pituitary Hormone Deficiency
Objective: Recent reports have indicated the role of the prokineticin receptor 2 gene (PROKR2) in the etiology of pituitary hormone deficiencies, suggesting a potential role for the PROK2 pathway in pituitary development, in addition to its role in gonadotropin releasing hormone-expressing neuron development. Here, we present the clinical and molecular findings of four patients with PROKR2 mutations.Methods: Next-generation targeted sequencing was used to screen 25 genes in 59 unrelated patients with multiple pituitary hormone deficiency (MPHD), isolated growth hormone (GH) deficiency, or idiopathic short stature.Results: Two different, very rare PROKR2 missense alterations classified as pathogenic (NM_144773.4:c.518T>G; NP_658986.1:p. (Leu173Arg)) and likely pathogenic (NM_144773.4:c.254G>A; NP_658986.1:p.(Arg85His)) were identified in four patients in heterozygous form. Patient 1 and Patient 2 presented with short stature and were diagnosed as GH deficiency. Patient 3 and Patient 4 presented with central hypothyroidism and cryptorchidism and were diagnosed as MPHD. No other pathogenic alterations were detected in the remaining 24 genes related to short stature, MPHD, and hypogonadotropic hypogonadism. Segregation analysis revealed asymptomatic or mildly affected carriers in the families.Conclusion: PROKR2 dominance should be kept in mind as a very rare cause of GH deficiency and MPHD. Expressional variation or lack of penetrance may imply oligogenic inheritance or other environmental modifiers in individuals who are heterozygous carriers.
- 21 November 2023
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 15 (4) , 338-347
Open AccessPROKR2 Mutations in Patients with Short Stature Who Have Isolated Growth Hormone Deficiency and Multiple Pituitary Hormone Deficiency
Objective: Recent reports have indicated the role of the prokineticin receptor 2 gene (PROKR2) in the etiology of pituitary hormone deficiencies, suggesting a potential role for the PROK2 pathway in pituitary development, in addition to its role in gonadotropin releasing hormone-expressing neuron development. Here, we present the clinical and molecular findings of four patients with PROKR2 mutations.Methods: Next-generation targeted sequencing was used to screen 25 genes in 59 unrelated patients with multiple pituitary hormone deficiency (MPHD), isolated growth hormone (GH) deficiency, or idiopathic short stature.Results: Two different, very rare PROKR2 missense alterations classified as pathogenic (NM_144773.4:c.518T>G; NP_658986.1:p. (Leu173Arg)) and likely pathogenic (NM_144773.4:c.254G>A; NP_658986.1:p.(Arg85His)) were identified in four patients in heterozygous form. Patient 1 and Patient 2 presented with short stature and were diagnosed as GH deficiency. Patient 3 and Patient 4 presented with central hypothyroidism and cryptorchidism and were diagnosed as MPHD. No other pathogenic alterations were detected in the remaining 24 genes related to short stature, MPHD, and hypogonadotropic hypogonadism. Segregation analysis revealed asymptomatic or mildly affected carriers in the families.Conclusion: PROKR2 dominance should be kept in mind as a very rare cause of GH deficiency and MPHD. Expressional variation or lack of penetrance may imply oligogenic inheritance or other environmental modifiers in individuals who are heterozygous carriers.
- 23 June 2023
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 19 (2) , 222-228
Clinical and Molecular Findings of Nine Cases with Tay-Sachs Disease From Türkiye
- 23 June 2023
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 19 (2) , 222-228
Clinical and Molecular Findings of Nine Cases with Tay-Sachs Disease From Türkiye
- 17 April 2023
- Published by Wiley in Clinical Genetics
- Vol. 104 (2) , 251-258
Revisiting TOP2B‐related phenotypes: Three new cases and literature review
DNA Topoisomerase II beta (TOP2B) acts on DNA topology during transcription and has a critical role in neural development. Heterozygous pathogenic changes in its encoding gene, TOP2B (MIM *126431), has been linked with three overlapping phenotypes characterized by immunodeficiency, acral and urogenital anomalies: Hoffman, BILU and Ablepharon-macrostomia-like syndrome. We herein report on a mother and two sons with distinct TOP2B-phenotype. Two males reported further delineated genital phenotype of males and all reported patients were reviewed for genotypephenotype correlation. We believe the patients reported herein along with the previously defined 11 represent a phenotypic spectrum from mild-to-severe immunological, acral and urogenital involvement, for which we propose the acronym "TOP2B-related Immunodeficiency and Congenital Anomalies Spectrum (TICAS)".
- 17 April 2023
- Published by Wiley in Clinical Genetics
- Vol. 104 (2) , 251-258
Revisiting TOP2B‐related phenotypes: Three new cases and literature review
DNA Topoisomerase II beta (TOP2B) acts on DNA topology during transcription and has a critical role in neural development. Heterozygous pathogenic changes in its encoding gene, TOP2B (MIM *126431), has been linked with three overlapping phenotypes characterized by immunodeficiency, acral and urogenital anomalies: Hoffman, BILU and Ablepharon-macrostomia-like syndrome. We herein report on a mother and two sons with distinct TOP2B-phenotype. Two males reported further delineated genital phenotype of males and all reported patients were reviewed for genotypephenotype correlation. We believe the patients reported herein along with the previously defined 11 represent a phenotypic spectrum from mild-to-severe immunological, acral and urogenital involvement, for which we propose the acronym "TOP2B-related Immunodeficiency and Congenital Anomalies Spectrum (TICAS)".
- 17 November 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (2) , 498-509
Fetal skeletal dysplasia cohort of a single tertiary referral center in Istanbul, Turkey
We report on 314 fetal cases from 297 unrelated families with skeletal dysplasia evaluated in the postmortem period from 2000 to 2017 at a single clinical genetics center in Istanbul, Turkey. The definite diagnostic yield was 40% during the prenatal period, while it reached 74.5% when combined with postmortem clinical and radiological evaluation. Molecular analyses were performed in 25.5% (n: 76) of families, and 21 novel variants were identified. Classification according to International Skeletal Dysplasia Society-2019 revision revealed limb hypoplasia-reduction defects group (39) as the leading one, 24.5%, then followed by FGFR3 chondrodysplasias, osteogenesis imperfecta, and decreased mineralization and polydactyly-syndactyly-triphalangism groups 13.6, 11.1, and 8.9%, respectively. The inheritance pattern was autosomal recessive in 54% and autosomal dominant in 42.6% of index cases. The overall consanguinity rate of the cohort was 33%. The high prevalence of ultrarare diseases along with two or more unrelated autosomal recessive entities running in the same family was noteworthy. This study highlights the pivotal role of postmortem evaluation by an experienced clinical geneticist to achieve a high diagnostic yield in fetal skeletal dysplasia cohorts. The cohort is not only a representation of the spectrum of skeletal dysplasias in a population with a high consanguinity rate but also provides an ideal research group to work on to identify the unknowns of early fetal life.
- 17 November 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (2) , 498-509
Fetal skeletal dysplasia cohort of a single tertiary referral center in Istanbul, Turkey
We report on 314 fetal cases from 297 unrelated families with skeletal dysplasia evaluated in the postmortem period from 2000 to 2017 at a single clinical genetics center in Istanbul, Turkey. The definite diagnostic yield was 40% during the prenatal period, while it reached 74.5% when combined with postmortem clinical and radiological evaluation. Molecular analyses were performed in 25.5% (n: 76) of families, and 21 novel variants were identified. Classification according to International Skeletal Dysplasia Society-2019 revision revealed limb hypoplasia-reduction defects group (39) as the leading one, 24.5%, then followed by FGFR3 chondrodysplasias, osteogenesis imperfecta, and decreased mineralization and polydactyly-syndactyly-triphalangism groups 13.6, 11.1, and 8.9%, respectively. The inheritance pattern was autosomal recessive in 54% and autosomal dominant in 42.6% of index cases. The overall consanguinity rate of the cohort was 33%. The high prevalence of ultrarare diseases along with two or more unrelated autosomal recessive entities running in the same family was noteworthy. This study highlights the pivotal role of postmortem evaluation by an experienced clinical geneticist to achieve a high diagnostic yield in fetal skeletal dysplasia cohorts. The cohort is not only a representation of the spectrum of skeletal dysplasias in a population with a high consanguinity rate but also provides an ideal research group to work on to identify the unknowns of early fetal life.